DPP4 and hydrops fetalis: This finding is consistent with those of previous trials in which saxagliptin treatment significantly increased the risk of HF, especially among patients with a high cardiovascular risk, whereas no such increase was detected with other DPP-4 inhibitors except saxagliptin.[18] Furthermore, vildagliptin, a peptidomimetic DPP-4 inhibitor similar to saxagliptin, demonstrated a decreased risk of hospitalization for CVDs (aHR, 0.77; 95% CI, 0.60–0.98).